About_editors 1..1 - Free

Glucan Synthase Inhibitors 3755. Serrano MC, Valverde-Conde A, Chavez MM, et al. In vitro activity of voriconazole,itraconazole, caspofungin, anidulafungin (VER002, LY303366) and amphotericin B againstAspergillus spp. Diagn Microbiol Infect Dis 2003; 45:131–135.6. Espinel-Ingroff A. Comparison of In vitro activities of the new triazole SCH56592 and theechinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous anddimorphic fungi and yeasts. J Clin Microbiol 1998; 36:2950–2956.7. Onishi J, Meinz M, Thompson J, et al. Discovery of novel antifungal (1,3)-beta-D-glucansynthase inhibitors. Antimicrob Agents Chemother 2000; 44:368–377.8. Abi-Said D, Anaissie E, Uzun O, Raad I, Pinzcowski H, Vartivarian S. The epidemiology ofhematogenous candidiasis caused by different Candida species. Clin Infect Dis 1997; 24:1122–1128.9. Nguyen MH, Peacock JE Jr, Morris AJ, et al. The changing face of candidemia: emergence ofnon-Candida albicans species and antifungal resistance. Am J Med 1996; 100:617–623.10. Nguyen MH, Clancy CJ, Yu VL, et al. Do in vitro susceptibility data predict the microbiologicresponse to amphotericin B? Results of a prospective study of patients with Candidafungemia. J Infect Dis 1998; 177:425–430.11. Gumbo T, Isada CM, Hall G, Karafa MT, Gordon SM. Candida glabrata Fungemia. Clinicalfeatures of 139 patients. Medicine (Baltimore) 1999; 78:220–227.12. Gumbo T, Chemaly RF, Isada CM, Hall GS, Gordon SM. Late complications of Candida(Torulopsis) glabrata fungemia: description of a phenomenon. Scand J Infect Dis 2002; 34:817–818.13. Clancy CJ, Barchiesi F, Falconi DL, et al. Clinical manifestations and molecular epidemiologyof late recurrent candidemia, and implications for management. Eur J Clin Microbiol InfectDis 2000; 19:585–592.14. Wingard JR, Kubilis P, Lee L, et al. Clinical significance of nephrotoxicity in patientstreated with amphotericin B for suspected or proven aspergillosis. Clin Infect Dis 1999;29:1402–1407.15. Bates DW, Su L, Yu DT, et al. Mortality and costs of acute renal failure associated withamphotericin B therapy. Clin Infect Dis 2001; 32:686–693.16. Drusano GL. Antimicrobial pharmacodynamics: critical interactions of “bug and drug.”Nat Rev Microbiol 2004; 2:289–300.17. Singer SJ, Nicolson GL. The fluid mosaic model of the structure of cell membranes. Science1972; 175:720–731.18. Fleet GH. Composition and structure of yeast cell walls. Curr Top Med Mycol 1985; 1:24–56.19. Douglas CM, D'Ippolito JA, Shei GJ, et al. Identification of the FKS1 gene of Candida albicansas the essential target of 1,3-beta-D-glucan synthase inhibitors. Antimicrob Agents Chemother1997; 41:2471–2479.20. Debono M, Gordee RS. Antibiotics that inhibit fungal cell wall development. Annu RevMicrobiol 1994; 48:471–497.21. Douglas CM. Fungal b (1,3)-D-glucan synthesis. Med Mycol 2001; 39(suppl 1):55–66.22. National Committee for Clinical Laboratory Standards Reference method for dilution antifungalsusceptibility testing of yeast; approved standards. NCCLS document M27-A2.Wayne, PA: National Committee for Clinical Laboratory Standards, 2002.23. Ostrosky-Zeichner L, Rex JH, Pappas PG, et al. Antifungal susceptibility survey of 2,000bloodstream Candida isolates in the United States. Antimicrob Agents Chemother 2003;47:3149–3154.24. Yamaguchi H et al. Antifungal mechanisms of micafungin: enzymological and morphologicalstudies of micafungin against Candida albicans and Aspergillus fumigatus. Chemotherapy(Tokyo) 2002; 50(S-1):20–29.25. Espinel-Ingroff A. Evaluation of broth microdilution testing parameters and agar diffusionEtest procedure for testing susceptibilities of Aspergillus spp. to caspofungin acetate (MK-0991). J Clin Microbiol 2003; 41:403–409.26. Arikan S, Lozano-Chiu M, Paetznick V, Rex JH. In vitro susceptibility testing methods forcaspofungin against Aspergillus and Fusarium isolates. Antimicrob Agents Chemother 2001;45:327–330.27. Rex JH, Pfaller MA, Galgiani JN, et al. Development of interpretive breakpoints for antifungalsusceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data